IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy ...

dCenter for Global Child Health Research, Department of Pediatrics, Division of Pulmonary and Critical Care Medicine, Oregon Health and Science University and the Portland VA Medical Center, Portland, ...

School of Veterinary Medicine, Faculty of Health and Medical Sciences. Arnoud graduated in 1991 from Utrecht University, The Netherlands, studying Medical Biology. He obtained his PhD in 1995 from the ...

Correspondence to Dr Felicity Fitzgerald, UCL Great Ormond Street of Child Health, 30 Guilford Street, London WC1N 1EH, UK; felicity.fitzgerald{at}ucl.ac.uk PCRs have revolutionised the detection of ...

gDepartment of Paediatrics and Child Health, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa ...

Emerging antibiotic resistance in bacteria endorses the failure of existing drugs with chronic illness, complicated treatment, and ever-increasing expenditures. Bacteria acquire the nature to adapt to ...

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.analchem.1c00663. (Figures S1–S10) Structural and color changes ...

The mechanisms by which antigens specifically sensitize lymphocytes to induce immunity are well recognized. The past decade has witnessed an increased awareness of the importance of specific ...

Mycobacterial disease is an immense burden worldwide. This disease group includes tuberculosis, leprosy (Hansen’s disease), Buruli Ulcer, and non-tuberculous mycobacterial (NTM) disease. The burden of ...

1 Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. 2 Centre for Microbiology Research, Kenya Medical Research Institute, ...